SI1899378T1 - IL-1Beta vezavna protitelesa in njihovi fragmenti - Google Patents

IL-1Beta vezavna protitelesa in njihovi fragmenti

Info

Publication number
SI1899378T1
SI1899378T1 SI200630518T SI200630518T SI1899378T1 SI 1899378 T1 SI1899378 T1 SI 1899378T1 SI 200630518 T SI200630518 T SI 200630518T SI 200630518 T SI200630518 T SI 200630518T SI 1899378 T1 SI1899378 T1 SI 1899378T1
Authority
SI
Slovenia
Prior art keywords
fragments
binding antibodies
beta binding
seq
amino acid
Prior art date
Application number
SI200630518T
Other languages
English (en)
Inventor
Linda Masat
Mary Haak-Frendscho
Gang Cheng
Arnold Horwitz
Marina Roell
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Publication of SI1899378T1 publication Critical patent/SI1899378T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
SI200630518T 2005-06-21 2006-06-21 IL-1Beta vezavna protitelesa in njihovi fragmenti SI1899378T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69283005P 2005-06-21 2005-06-21
EP06773749A EP1899378B1 (en) 2005-06-21 2006-06-21 Il-1 beta binding antibodies and fragments thereof

Publications (1)

Publication Number Publication Date
SI1899378T1 true SI1899378T1 (sl) 2010-02-26

Family

ID=37595818

Family Applications (4)

Application Number Title Priority Date Filing Date
SI200631713T SI2163562T1 (sl) 2005-06-21 2006-06-21 IL-1 beta vezavna protitelesa in njihovi fragmenti
SI200631432T SI2314623T1 (sl) 2005-06-21 2006-06-21 IL beta vezavna protitelesa in njihovi fragmenti
SI200630518T SI1899378T1 (sl) 2005-06-21 2006-06-21 IL-1Beta vezavna protitelesa in njihovi fragmenti
SI200632052A SI2322552T1 (sl) 2005-06-21 2006-06-21 IL-1beta vezavna protitelesa in njihovi fragmenti

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200631713T SI2163562T1 (sl) 2005-06-21 2006-06-21 IL-1 beta vezavna protitelesa in njihovi fragmenti
SI200631432T SI2314623T1 (sl) 2005-06-21 2006-06-21 IL beta vezavna protitelesa in njihovi fragmenti

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200632052A SI2322552T1 (sl) 2005-06-21 2006-06-21 IL-1beta vezavna protitelesa in njihovi fragmenti

Country Status (24)

Country Link
US (11) US7531166B2 (sl)
EP (5) EP2163562B1 (sl)
JP (2) JP4931919B2 (sl)
KR (3) KR101502920B1 (sl)
CN (2) CN102775493B (sl)
AT (1) ATE446972T1 (sl)
AU (1) AU2006262179B2 (sl)
BR (1) BRPI0612273C1 (sl)
CA (2) CA2873914A1 (sl)
CY (3) CY1109715T1 (sl)
DE (1) DE602006010072D1 (sl)
DK (4) DK2314623T3 (sl)
ES (5) ES2439709T3 (sl)
HK (3) HK1157351A1 (sl)
HU (1) HUE029021T2 (sl)
IL (2) IL188094A (sl)
MX (2) MX2007016032A (sl)
NZ (1) NZ565138A (sl)
PL (4) PL2314623T3 (sl)
PT (3) PT1899378E (sl)
RU (1) RU2518295C2 (sl)
SI (4) SI2163562T1 (sl)
WO (1) WO2007002261A2 (sl)
ZA (1) ZA200800555B (sl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931919B2 (ja) * 2005-06-21 2012-05-16 ゾーマ テクノロジー リミテッド ＩＬ−１β結合抗体およびその断片
CN101291693B (zh) 2005-10-26 2012-10-03 诺瓦提斯公司 IL-1β化合物的新用途
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2068889B1 (en) 2006-08-10 2019-10-23 Roy C. Levitt Anakinra for use in the treatment of bronchiolitis obliterans syndrome
CA2673592C (en) * 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
CA3030662C (en) * 2007-05-29 2020-06-30 Novartis Ag New indications for anti-il-1-beta therapy
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
WO2009086003A1 (en) 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
PL2293816T3 (pl) * 2008-06-06 2013-04-30 Xoma Us Llc Sposoby leczenia reumatoidalnego zapalenia stawów
WO2010028275A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
AR073997A1 (es) * 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
UA102722C2 (en) * 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2427209A1 (en) * 2009-05-06 2012-03-14 Novartis AG Anti-il1- antibody combination therapy
SG2014014534A (en) * 2009-05-29 2014-07-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
ES2617180T3 (es) 2009-09-03 2017-06-15 Ablynx N.V. Formulaciones estables de polipéptidos y uso de las mismas
US9885711B2 (en) * 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
EP2488201A4 (en) * 2009-10-15 2013-12-25 Abbvie Inc IL-1 BINDING PROTEINS
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
SG2014014724A (en) * 2010-05-07 2014-07-30 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
US9085621B2 (en) 2010-09-10 2015-07-21 Apexigen, Inc. Anti-IL-1β antibodies
WO2012109373A2 (en) * 2011-02-08 2012-08-16 Abbott Laboratories Treatment of osteoarthritis and pain
JP2014519480A (ja) 2011-04-15 2014-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌で使用される抗ｉｌ−１ｒ１阻害物質
AU2012262675B2 (en) 2011-06-03 2016-05-19 Mesoblast, Inc Methods of treating or preventing neurological diseases
EP2731971A1 (en) 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
TWI461192B (zh) * 2011-07-20 2014-11-21 Twi Biotechnology Inc 降低血脂異常病患之糖化血色素的醫藥組成物
DE102011083595A1 (de) * 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
AU2012316083A1 (en) 2011-09-30 2014-04-17 Novartis Ag Use of IL-1 beta binding antibodies
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP2623604B8 (en) * 2012-02-02 2015-04-22 Baylor College of Medicine Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
WO2013122544A2 (en) * 2012-02-13 2013-08-22 Agency For Science, Technology And Research IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2014033252A1 (en) * 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
EP2914287B1 (en) * 2012-11-05 2020-03-18 Delenex Therapeutics AG Binding members to il-1 beta
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
LT2956471T (lt) * 2013-02-15 2024-06-10 R-Pharm International, Llc Il-1beta inhibitoriaus kompozicija ir jos naudojimas
WO2014194166A1 (en) * 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
BR112016013347B1 (pt) * 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
WO2016008851A1 (en) * 2014-07-14 2016-01-21 Boehringer Ingelheim International Gmbh Anti-il-1b antibodies
US20180155388A1 (en) 2015-05-18 2018-06-07 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulator (sprm) regimen
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN108218978B (zh) * 2016-12-13 2020-05-12 沈阳何氏眼产业集团有限公司 一种重组白细胞介素18及其制备方法与应用
WO2018112256A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology CELL ATLAS OF HEALTHY AND DISEASED BARRIER TISSUE
BR112020003458A2 (pt) 2017-08-31 2020-08-25 Mitsubishi Tanabe Pharma Corporation agente terapêutico contendo antagonistas il-33 para endometriose
MX2020002813A (es) 2017-09-13 2020-07-21 Novartis Ag Uso de anticuerpos de union a il-1b para el tratamiento de la hepatitis alcoholica.
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
US20230020548A1 (en) 2019-12-09 2023-01-19 Novartis Ag Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CA3165274A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
JP2023511236A (ja) * 2020-01-21 2023-03-16 タボテック バイオセラピューティクス （ホンコン） リミテッド ＩＬ－１β受容体シグナル伝達に干渉する剤
WO2022167916A1 (en) 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
CN114524875B (zh) * 2021-11-11 2023-07-25 江苏莱森生物科技研究院有限公司 偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493543A (en) * 1893-03-14 Lap-ring
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
DE3587669T2 (de) 1984-05-18 1994-03-31 New England Medical Center Inc Menschliche IL-1-cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren.
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5474899A (en) 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5077218A (en) * 1988-05-05 1991-12-31 Oregon Lions Sight And Hearing Foundation Inc. Eye transport apparatus
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE68925935T2 (de) * 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2113856T3 (es) * 1989-02-27 1998-05-16 New England Medical Center Inc Inhibidores de actividad biologica de il-1.
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
AU695323B2 (en) 1994-09-09 1998-08-13 Takeda Chemical Industries Ltd. Sustained release preparation containing metal salt of a peptide
JPH10507637A (ja) * 1994-10-20 1998-07-28 メルク エンド カンパニー インコーポレーテッド インターロイキン−１β欠損トランスジェニック動物
CN101829325A (zh) * 1994-10-21 2010-09-15 岸本忠三 Il-6受体的抗体在制备药物组合物中的用途
AU695207B2 (en) 1995-03-28 1998-08-06 Fidia Farmaceutici S.P.A. Nanospheres comprising a biocompatible polysaccharide
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
BR9608542A (pt) 1995-06-07 1999-11-30 Alkermes Inc Composição para a liberação sustentada de hormónio do crescimento humano
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6455254B1 (en) 1995-07-18 2002-09-24 Diversa Corporation Sequence based screening
US6057103A (en) 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US6168919B1 (en) 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
US6004788A (en) 1995-07-18 1999-12-21 Diversa Corporation Enzyme kits and libraries
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6344328B1 (en) 1995-12-07 2002-02-05 Diversa Corporation Method for screening for enzyme activity
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US20030215798A1 (en) 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6489145B1 (en) 1996-07-09 2002-12-03 Diversa Corporation Method of DNA shuffling
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6368798B1 (en) 1995-12-07 2002-04-09 Diversa Corporation Screening for novel bioactivities
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6380162B1 (en) * 1996-10-31 2002-04-30 Applied Research Systems Ars Holding N.V. Ice inhibiting peptides
EP0977779A1 (en) * 1997-04-21 2000-02-09 Schering Corporation Mammalian cytokines; related reagents and methods
AU4441699A (en) 1998-06-17 2000-01-05 Maxygen, Inc. Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
CA2362737A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6864047B2 (en) 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
JP2004536605A (ja) * 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
AU2002351505B2 (en) 2001-10-19 2008-04-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US6673552B2 (en) 2002-01-14 2004-01-06 Diversa Corporation Methods for purifying annealed double-stranded oligonucleotides lacking base pair mismatches or nucleotide gaps
JP2005518802A (ja) 2002-02-28 2005-06-30 イーライ・リリー・アンド・カンパニー 抗インターロイキン−１ベータ類縁体
US7572770B2 (en) 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
US7438910B2 (en) 2002-09-06 2008-10-21 Amgen Inc. Therapeutic human anti-IL1-R1 monoclonal antibody
CA2503886A1 (en) 2002-11-01 2004-05-13 Alk-Abello A/S Recombinant protein variants
EP1590369B1 (en) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040266993A1 (en) 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides
WO2005019259A2 (en) 2003-08-25 2005-03-03 Compugen Ltd. Variants of interleukin-1 receptor antagonist: compositions and uses thereof
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
WO2005084696A1 (en) 2004-03-08 2005-09-15 Universita'degli Studi Di Milano Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
JP4931919B2 (ja) 2005-06-21 2012-05-16 ゾーマ テクノロジー リミテッド ＩＬ−１β結合抗体およびその断片
FR2895611B1 (fr) 2005-12-23 2008-02-22 Thales Sa Architecture et procede pour controler le transfert d'informations entre utilisateurs
US8479265B2 (en) * 2008-07-02 2013-07-02 Oracle International Corporation Usage based authorization

Also Published As

Publication number Publication date
MX2007016032A (es) 2008-03-10
JP2011254835A (ja) 2011-12-22
US7744865B2 (en) 2010-06-29
RU2518295C2 (ru) 2014-06-10
EP3056511A2 (en) 2016-08-17
EP1899378A2 (en) 2008-03-19
US8377442B2 (en) 2013-02-19
US7744866B2 (en) 2010-06-29
IL188094A (en) 2011-01-31
AU2006262179A1 (en) 2007-01-04
SI2322552T1 (sl) 2016-07-29
HK1140781A1 (en) 2010-10-22
US20090226461A1 (en) 2009-09-10
SI2314623T1 (sl) 2012-11-30
WO2007002261A3 (en) 2007-07-12
US20090214568A1 (en) 2009-08-27
US20080044414A1 (en) 2008-02-21
ES2439709T3 (es) 2014-01-24
NZ565138A (en) 2012-02-24
MX348154B (es) 2017-05-30
EP2314623B1 (en) 2012-07-04
ES2391334T3 (es) 2012-11-23
DK2163562T3 (da) 2013-12-09
EP2163562A3 (en) 2010-10-20
US7829094B2 (en) 2010-11-09
PL2322552T3 (pl) 2016-08-31
ATE446972T1 (de) 2009-11-15
US7582742B2 (en) 2009-09-01
CY1114851T1 (el) 2016-12-14
EP2163562A2 (en) 2010-03-17
KR20080039875A (ko) 2008-05-07
KR20130076901A (ko) 2013-07-08
US7943121B2 (en) 2011-05-17
US7829093B2 (en) 2010-11-09
US20090060923A1 (en) 2009-03-05
US20100061998A1 (en) 2010-03-11
BRPI0612273B8 (pt) 2020-01-14
US9206252B2 (en) 2015-12-08
KR101502920B1 (ko) 2015-03-17
PT2314623E (pt) 2012-10-02
US20090214545A1 (en) 2009-08-27
ES2569917T3 (es) 2016-05-13
CY1113153T1 (el) 2016-04-13
PL1899378T3 (pl) 2011-03-31
CA2612760A1 (en) 2007-01-04
JP4931919B2 (ja) 2012-05-16
EP2322552A3 (en) 2011-07-20
KR20140139618A (ko) 2014-12-05
HK1158218A1 (zh) 2012-07-13
IL188094A0 (en) 2008-03-20
CN102775493A (zh) 2012-11-14
SI2163562T1 (sl) 2014-01-31
EP3056511A3 (en) 2016-11-23
ES2335232T3 (es) 2010-03-23
DE602006010072D1 (de) 2009-12-10
KR101366450B1 (ko) 2014-03-14
BRPI0612273C1 (pt) 2021-05-25
EP1899378B1 (en) 2009-10-28
WO2007002261A2 (en) 2007-01-04
ES2827247T3 (es) 2021-05-20
JP2008543340A (ja) 2008-12-04
PT2163562E (pt) 2013-12-19
CA2873914A1 (en) 2007-01-04
EP2322552B1 (en) 2016-02-10
IL202630A (en) 2011-01-31
CN102775493B (zh) 2015-10-28
DK1899378T3 (da) 2010-02-01
EP2163562B1 (en) 2013-09-18
EP3056511B1 (en) 2020-08-05
US20100055110A1 (en) 2010-03-04
US7988968B2 (en) 2011-08-02
RU2008102135A (ru) 2009-07-27
HK1157351A1 (en) 2012-06-29
US7695717B2 (en) 2010-04-13
PT1899378E (pt) 2010-01-26
CY1109715T1 (el) 2014-08-13
EP2322552A2 (en) 2011-05-18
US20090246210A1 (en) 2009-10-01
EP2314623A1 (en) 2011-04-27
US20140004125A1 (en) 2014-01-02
ZA200800555B (en) 2009-09-30
CA2612760C (en) 2015-05-12
DK2314623T3 (da) 2012-09-17
HUE029021T2 (en) 2017-02-28
US7531166B2 (en) 2009-05-12
BRPI0612273A2 (pt) 2009-01-27
PL2163562T3 (pl) 2014-03-31
AU2006262179B2 (en) 2011-05-12
CN101228188A (zh) 2008-07-23
US20120014967A1 (en) 2012-01-19
DK2322552T3 (en) 2016-04-25
BRPI0612273B1 (pt) 2019-02-05
US20090060918A1 (en) 2009-03-05
PL2314623T3 (pl) 2012-11-30

Similar Documents

Publication Publication Date Title
PT1899378E (pt) Anticorpos de ligação de il-1β e os seus fragmentos
NZ596295A (en) Anti-5T4 antibodies and uses thereof
DK1392359T3 (da) Specifikke bindingsproteiner og deres anvendelser
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CY1109149T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
IN2009KN02655A (sl)
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
WO2004106367A3 (en) Enterococcus antigens
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE602004024179D1 (de) Staphylococcus epidermidis antigene
ATE531799T1 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper
WO2009083968A8 (en) Novel protein
CY1117395T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
TH87431B (th) แอนติบอดีชนิดแอนติ-il-12, เอพิโทป, สารผสม, วิธี และการใช้